 Emmaus Life Sciences Inc OTCQX:EMMA has announced the approval of its application for marketing authorization of its Endari sickle cell treatment from the United Arab Emirates UAE Ministry of Health after a five-month review. During the review period, Endari was available in the UAE on a named patient, or early access, basis only. 